The last time I wrote about 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), it was in a Seeking Alpha article entitled “4d Molecular Therapeutics: Several Value Inflection Points To Watch In 2024.” In ...
4D Molecular Therapeutics announced an acceleration in the timeline for its 4FRONT-1 Phase 3 trial data readout of the 4D-150 treatment for wet age-related macular degeneration (AMD), now expected in ...
TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular ...
Astellas Pharma is digging up some cash to use one of 4D Molecular Therapeutics’ gene therapy vectors for at least one rare eye disease—but the genetic medicines company is going to have to wait a ...
Please provide your email address to receive an email when new articles are posted on . Astellas has gained the rights to utilize 4DMT’s R100 vector to deliver its unique genetic payloads. Astellas is ...
Julie Clark, M.D., promoted to Chief Medical Officer Liansheng Zhu, Ph.D., joined as SVP, Biometrics and Data Quality4FRONT-1 Phase 3 trial ...
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is one of the stocks Jim Cramer answered questions about recently. A caller asked Cramer for his opinion on the stock, and noted that it was rated a ...
TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (FDMT) (CEO: David Kirn, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback